NCAPG2

Across TCGA pan-cancer cohorts, NCAPG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NCAPG2 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NCAPG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NCAPG2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where NCAPG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.178	0.586	<.001	100	view →
LUAD	OS	Tertile	II,III,IV	0.320	0.893	.006	19	view →
CCRCC	DFS	Median	II,III,IV	0.887	0.198	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NCAPG2–PDAC (DFS)

Open the PDAC breakdown →